Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors

Journal of Medicinal Chemistry

Volumn 46, Issue 11, 2003, Pages 2027-2030

  Zhu, Guoxin ^a   Conner, Scott E ^a   Zhou, Xun ^a   Shih, Chuan ^a   Li, Tiechao ^a   Anderson, Bryan D ^a   Brooks, Harold B ^a   Morris Campbell, Robert ^a   Considine, Eileen ^a   Dempsey, Jack A ^a   Faul, Margaret M ^a   Ogg, Cathy ^a   Patel, Bharvin ^a   Schultz, Richard M ^a   Spencer, Charles D ^a   Teicher, Beverly ^a   Watkins, Scott A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; INDOLOCARBAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PROTEIN PHOSPHORYLATION; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ANTINEOPLASTIC AGENTS; CARBAZOLES; CELL DIVISION; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASES; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; G1 PHASE; HUMANS; INDOLES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; RETINOBLASTOMA PROTEIN; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0037573393     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0256169     Document Type: Article

References (45)

1. (a) Dynlacht, B. D. Regulation of transcription by proteins that control the cell cycle. Nature 1997, 389, 149-152.
2. (b) Elledge, S. J. Cell cycle checkpoints: Preventing an identity crisis. Science 1996, 274, 1664-1671.
3. (a) Pines, J. Four-dimensional control of the cell cycle. Nat. Cell Biol. 1999, 1, E73-E79.
4. Morgan, D. O. Cyclin dependent kinases: Engines, clocks and microprocessors. Annu. Rev. Cell Dev. Biol. 1997, 13, 261-291.
5. (a) Hartwell, L. H.; Kastan, M. B. Cell cycle control and cancer. Science 1994, 266, 1821-1828.
6. (b) Kamb, A.; Gruis, N. A.; Weaver-Feldhaus, J.; Liu, Q.; Harshman, K.; Tavtigian, S. V.; Stockert, E.; Day, R. S.; Johnson, B. E., III; Skolnick, M. H. A cell cycle regulator, potentially involved in genesis of many tumor types. Science 1994, 264, 436-440.
7. (c) Palmero, I.; Peters, G. Perturbation of cell cycle regulators in human cancer. Cancer Surv. 1996, 27, 351-367.
8. (d) Kim, H.; Ham, E. K.; Kim, Y. I.; Chi, J. G.; Lee, H. S.; Park, S. H.; Jung, Y. M.; Myung, N. K.; Lee, M. J.; Jang, J. J. Overexpression of cyclin D1 and cdk4 in tumorigenesis of sporadic hepatoblastomas. Cancer Lett. 1998, 131, 77-83.
9. (a) Knockaert, M.; Greengard, P.; Meijer, L. Pharmacological inhibitors of cyclin dependent kinases. Trends Pharmacol. Sci. 2002, 23, 417-425.
10. (b) Senderowicz, A. M.; Sausville, E. A. Preclinical and clinical development of cyclin-dependent kinase modulators. J. Natl. Cancer Inst. 2000, 92, 376-387.
11. (c) Sielecki, T. M.; Boylan, J. F.; Benfield, P. A.; Trainor, G. L. Cyclin-dependent kinase inhibitors: Useful targets in cell cycle regulation. J. Med. Chem. 2000, 43, 1-18.
12. (d) Fry, D. W.; Darrett, M. D. Inhibitors of cyclin-dependent kinases as therapeutic agents for the treatment of cancer. Curr. Opin. Oncol. Endocr. Metab. Invest. Drugs 2000, 2, 40-59.
13. (e) Gray, N.; Detivaud, L.; Doerig, C.; Meijer, L. ATP-site directed inhibitors of cyclin-dependent kinases. Curr. Med. Chem. 1999, 6, 859-875.
14. (a) Senderowicz, A. M.; Headlee, D.; Stinson, S. F.; Lush, R. M.; Kalil, N.; Villaaba, L.; Hill, K.; Steinberg, S. M.; Figg, W. D.; Tompkins, A.; Arbuck, S. G.; Sausville, E. A. Phase I trial of continuous infusion Flavopiridol, a novel cyclin dependent kinase inhibitor, in patients with refractory neoplasms. J. Clin. Oncol. 1998, 16, 2986-2999.
15. (b) Kim, K. S.; Sack, J. S.; Tokarski, J. S.; Qian, L.; Chao, S. T.; Leith, L.; Kelly, Y. F.; Misra, R. N.; Hunt, J. T.; Kimball, S. D.; Humphreys, W. G.; Wautlet, B. S.; Mulheron, J. G.; Webster, K. R. Thio- and oxoflavopiridols, cyclin-dependent kinase 1 selective inhibitors: synthesis and biological effects. J. Med. Chem. 2000, 43, 4126-4134.
16. (a) Akinaga, S.; Sugiyama, K.; Akiyama, T. UCN-01 (7-hydroxystayrosporine) and other indolocarbazole compounds: a new generation of anticancer agents for the new century? Anti-Cancer Drug Des. 2000, 15, 43-52.
17. Raymond, E.; Laurence, V.; Faivre, S.; Vera, K.; Pierga, J.; Delbaldo, C.; Bekradda, M.; Armand, J.; Gianella-Borradori, A.; Dieras, V. Preliminary results of an ongoing phase I and pharmacokinetic study of CYC202, a novel oral cyclin-dependent kinases inhibitor, in patients with advanced malignancies AACR NCI EORTC Mol. Targets Cancer Ther. 2002, November, 19-22 (Abs 150).
18. Olomoucine: Alessi, F.; Quarta, S.; Savio, M.; Riva, F.; Rossi, L.; Stivala, L. A.; Scovassi, A. I.; Meijer, L.; Prosperi, E. The cyclin dependent kinase inhibitors Olomoucine and Roscovitine arrest human fibrablasts in G1 phase by specific inhibition of CDK2 kinase activity. Exp. Cell Res. 1998, 245, 8-18.
19. Peptide: Atkinson, G. E.; Cowan, A.; McInnes, C.; Zheleva, D. I.; Fischer, P. M.; Chan, W. C. Peptide inhibitors of CDK2-cyclin A that target the cyclin recruitment-site: Structural variants of the C-terminal Phe. Bioorg. Med. Chem. Lett. 2002, 2501-2505.
20. Butyrolactone: Kitagawa, M.; Okabe, T.; Ogino, H.; Matsumoto, H.; Suzuki-Takahashi, I.; Kokubo, T.; Higashi, H.; Saitoh, S.; Taya, Y.; Yasuda, H.; Ohba, Y.; Nishimura, S.; Tanaka, N.; Okuyama, A. Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinases. Oncogene 1993, 8, 2425-2432.
21. Paullones: (a) Zaharevitz, D. W.; Gussio, R.; Leost, M.; Senderowicz, A. M.; Lahusen, T.; Kunick, C.; Meijer, L.; Sausville, E. A. Discovery and initial characterization of the paullones, a novel class of small molecule inhibitors of cyclin dependent kinases. Cancer Res. 1999, 59, 2566-2569.
22. (b) Schultz, C.; Link, A.; Leost, M.; Zaharevitz, D. W.; Gussio, R.; Sausville, E. A. Paullones, a series of cyclin dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. J. Med. Chem. 1999, 42, 2909-2919.
23. Indirubins: Hoessel, R.; Leclerc, S.; Endicott, J. A.; Nobel, M. E. M.; Lawrie, A.; Tunnah, P.; Leost, M.; Damiens, E.; Marie, D.; Marko, D.; Niederberger, E.; Tang, W.; Eisenbrand, G.; Meijer, L.; Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin dependent kinases. Nat. Cell Biol. 1999, 1, 60-67.
24. Oxindoles: Bramson, H. N.; Corona, J.; Davis, S. T.; Dikerson, S. H.; Edelstein, M.; Frye, S. V.; Gampe, R. T.; Harris, P. A.; Hassell, A.; Holmes, W. D.; Hunter, R. N.; Lackey, K. E.; Lovejoy, B.; Luzzio, M. J.; Montana, V.; Rocque, W. J.; Rusnak, D.; Schewchuk, L.; Veal, J. M.; Walker, D. H.; Kuyper, L. F. Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): Design, synthesis, enzymatic activities, and X-ray crystallographic analysis. J. Med. Chem. 2001, 44, 4339-4358.
25. Hymenialdisine: Meijer, L.; Thunnissen, A. M. W. H.; White, A. W.; Garnier, M.; Nikolic, M.; Tsai, L. H.; Walter, J.; Cleverley, K. E.; Salinas, P. C.; Wu, Y. Z.; Biernat, J.; Mandelkow, E. M.; Kim, S. H.; Pettit, G. R. Inhibition of cyclin-dependent kinases, GSK-3b and CK1 by hymenialdisine, a marine sponge constituent. Chem. Biol. 2000, 71, 51.
26. Purines: (a) Legraverend, M.; Tunnah, P.; Noble, M.; Ducrot, P.; Ludwig, O.; Grierson, D. S.; Leost, M.; Meijei, L.; Endicott, J. Cyclin dependent kinase inhibition by new C-2 alkynylated purine derivatives and molecular structure of a CDK2-inhibitor complex. J. Med Chem. 2000, 43, 1282-1292.
27. (b) de Azevedo, W. F., Jr.; LeClerc, S.; Meijer, L.; Havlicek, L.; Strnad, M.; Kim, S. H. Inhibition of cyclin-dependent kinases by purine analogues. Crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. 1997, 243, 518-526.
28. Indenopyrazoles: Nugiel, D. A; Etzkorn, A.-M.; Vidwans, A.; Benfield, P. A.; Boisclair, M.; Burton, C. R.; Cox, S.; Czerniak, P. M.; Doleniak, D.; Seitz, S. P. Indenopyrazoles as novel cyclin dependent kinase (CDK) inhibitors. J. Med Chem. 2001, 44, 1334-1336.
29. β-Carbolines: Song, Y.; Wang, J.; Teng, S. F.; Kesuma, D.; Deng, Y.; Duan, J.; Wang, J. H.; Qi, R. Z.; Sim, M. M. β-Carbolines as specific inhibitors of cyclin dependent kinases. Bioorg. Med. Chem. Lett. 2002, 12, 1129-1132.
30. -Benziliden-benzofuranones: Scoepfer, J.; Fretz, H.; Chaudhuri, B.; Murler, L.; Seeber, E.; Meijer, L.; Lozach, O.; Vangrevelinghe, E.; Furet, P. Structural-based design and synthesis of 2-benzylidene-benzofuran-3-ones as flavopiridol mimics. J. Med. Chem. 2002, 45, 1741-1747.
31. Fascaplysin: Soni, R.; Muller, L.; Furet, P.; Schoepfer, J.; Stephan, C.; Zumstein-Mecker, S.; Fretz, H.; Chaudhuri, B. Inhibition of cyclin-dependent kinase 4 (CDK4) by fascaplysin, a marine natural product. Biochem. Biophys. Res. Commun. 2000, 275, 877-884.
32. -Arylamino-4,7-dioxobenzothiazoles: Ryu, C.-K.; Kang, H.-Y.; Lee, S. K.; Nam, K. A.; Hong, C. Y.; Ko, W.-G.; Lee, B.-H. 5-Arylamino-2-methyl-4,7-dioxobenzothiazoles as inhibitors of cyclin dependent kinase 4 and cytotoxic agents. Bioorg. Med. Chem. Lett. 2000, 10, 461-464.
33. Benzocarbazoles: Carini, D. J.; Kaltenbach, R. F., III; Liu, J.; Benfield, P. A.; Boylan, J.; Boisclair, M.; Brizuela, L.; Burton, C. R.; Cox, S.; Grafstrom, R.; Harrison, B. A.; Harrison, K.; Akamike, E.; Markwalder, J. A.; Nakano, Y.; Seitz, S. P.; Sharp, D. M.; Trainor, G. L.; Sielecki, T. M. Identification of selective inhibitors of cyclin dependent kinase 4. Bioorg. Med. Chem. Lett. 2001, 11, 2209-2211.
34. Pyrido [2,3-d]pyrimidin-7-ones: Fry, D. W.; Bedfords, D. C.; Harvey, P. H.; Fritsch, A.; Keller, P. R.; Wu, Z.; Dobrusin, E.; Leopold, W. R.; Fattaey, A.; Garrett, M. D. Cell cycle and biochemical effects of PD 0183812. J. Biol. Chem. 2001, 276, 16617-16623.
35. Cinamaldehydes: Jeong, H.-W.; Kim, M.-R.; Sun, K.-H.; Han, M. Y.; Ha, J.-H.; Ganier, M.; Meijer, L.; Kwan, B.-M. Cinnamaldehydes inhibit cyclin dependent kinase4/cyclin D1. Bioorg. Med. Chem. Lett. 2000, 10, 1819-1822.
36. Diarylureas: Honma, T.; Yoshizumi, T.; Hayashi, K.; Kawanishi, N.; Hashimoto, N.; Fukasawa, K.; Takaki, T.; Ikeura, C.; Ikuta, M.; Suzuki-Takahashi, I.; Hayama, T.; Nishimura, S.; Morishima, H. A novel approach for the development of selective CDK4 inhibitors: Library design based on locations of CDK4 specific amino acid residues. J. Med. Chem. 2001, 44, 4628-4640.
37. Quinazolines: Sielecki, T. M.; Johnson, T. L.; Liu, J.; Muckelbauer, J. K.; Grafstrom, R. H.; Cox, S.; Boylan, J.; Burton, C. R.; Chen, H.; Smallwood, A.; Chang, C. H.; Boisclair, M.; Benfield, P. A.; Trainor, G. L.; Seitz, S. P. Quinazolines as cyclin dependent kinase inhibitors. Bioorg. Med. Chem. Lett. 2001, 11, 1157-1160.
38. Konbuacidin A: Kobayashi, J.; Suzuki, M.; Tsuda, M. Konbu'acidin A, a new bromopyrrole alkloid with cdk4 inhibitory activity from Hymeniacidon Sponge. Tetrahedron 1997, 53, 15681-15684.
39. Joyce, R. P.; Gainor, J. A.; Weinreb, S. M. Synthesis of the aromatic and monosaccharide moieties of staurosporine. J. Org. Chem. 1987, 52, 1177.
40. Yields of cyclization: 4b, 39%; 4c, 88%; 4d, 79%; 4e, 80%; 4f, 67%; 4g, 80%; 4h, 55%; 4i, 67%; 4j, 75%; 4k, 69%; 4l, 60%; 4m, 60%.
41. (a) Faul, M. M.; Winneroski, L. L.; Kumrich, C. A new, efficient method for the synthesis of bisindolomaleimides. J. Org. Chem. 1998, 63, 6053-6058.
42. (b) Faul, M. M.; Winneroski, L. L.; Krumrich, C. A. A new one step synthesis of maleimides by condensation of glyoxylate esters with acetamides. Tetrahedron Lett. 1999, 40, 1109-1112.
43. Konstantinidis, A. K.; Radhakrishnan, R.; Gu, F.; Rao, R. N.; Yeh, W. K. Purification, characterization, and kinetic mechanism of cyclin D1-CDK4, a major target for cell cycle regulation. J. Biol. Chem. 1998, 273, 26506-26515.
44. Schultz, R. M.; Merriman, R. L.; Toth, J. E.; Zimmermann, J. E.; Hertel, L. W.; Andis, S. L.; Dudley, D. E.; Rutherford, P. G.; Tanzer, L. R.; Grindey, G. B. Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 Human Pancreatic Carcinoma Xenografts. Oncol. Res. 1993, 5, 223.
45. Brugarolas, J.; Moberg, K.; Boyd, S. D.; Taya, Y.; Jacks, T.; Lees, J. A. Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after γ-irradiation. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 1002-1007.